Hans Salwender

19PUBLICATIONS
87CO-AUTHORS
Gene and molecular therapyMedical mycologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Jun 25, 2026
Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.

|May 21, 2026
Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

|Nov 11, 2025
Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG-MM5 Trial.

Tim Richardson, Elias Mai, Ekaterina Menis

|Dec 09, 2024
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial.

Elias K Mai, Uta Bertsch, Ema Pozek

|Jul 10, 2024
Quantitative Integrative Survival Prediction in Multiple Myeloma Patients Treated With Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation.

Manuela Hummel, Thomas Hielscher, Martina Emde-Rajaratnam

|Feb 26, 2024
Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial.

Hans Salwender, Niels Weinhold, Axel Benner

Pageof 4

Frequent Collaborators

15 joint publications

Hartmut Goldschmidt

11 joint publications

Elias Mai

11 joint publications

Katja Weisel

9 joint publications

Marc S Raab